These results suggest that EGCG and SFN may exert similar epigenetic effects as shown in the demethylation agent and HDAC inhibitor, respectively, which may contribute to ERα reactivation in ERα(−) breast cancer. This evidence concerns the gene ESR1 and breast cancer.